Literature DB >> 25663411

Cognitive-behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia.

Christopher Kobylecki1, Matthew Jones, Jennifer C Thompson, Anna M Richardson, David Neary, David M A Mann, Julie S Snowden, Alexander Gerhard.   

Abstract

Cognitive impairment is common in patients with the neurodegenerative tauopathy progressive supranuclear palsy (PSP). Although a pattern of 'subcortical' cognitive impairment is considered prototypical in PSP, pathological and clinical observations suggest an overlap with frontotemporal dementia (FTD). Our objective was to evaluate behavioural and cognitive symptoms in a retrospective study of patients with PSP syndrome (PSPS) and their relationship to features seen in behavioural variant FTD. We reviewed the records of 62 patients (29 male, 33 female, median age 65.5 years) evaluated at a tertiary cognitive clinic who met NINDS-SPSP criteria for probable or possible PSP, and collected clinical details of their presenting history, cognitive and behavioural features. We also evaluated the proportion of patients fulfilling FTD Consensus criteria. Cognitive and behavioural symptoms were a predominant presenting feature in 58% of patients evaluated. Cognitive slowing, executive impairments, and inefficient memory recall, consistent with 'subcortical' impairment, were identified in the majority of patients. Twenty patients (32%) fulfilled cognitive and behavioural criteria for possible FTD at initial assessment, whereas behavioural changes not meeting formal diagnostic criteria were present in a greater proportion of the patients. Our findings support the existence of a spectrum of cognitive-behavioural features in PSPS, with significant clinical overlap with behavioural variant FTD. Cognitive and behavioural profiling should be an integral part of the assessment of patients with PSPS.

Entities:  

Mesh:

Year:  2015        PMID: 25663411     DOI: 10.1007/s00415-015-7657-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  31 in total

1.  PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.

Authors:  J C STEELE; J C RICHARDSON; J OLSZEWSKI
Journal:  Arch Neurol       Date:  1964-04

2.  Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy.

Authors:  Gesine Respondek; Sigrun Roeber; Hans Kretzschmar; Claire Troakes; Safa Al-Sarraj; Ellen Gelpi; Carles Gaig; Wang Zheng Chiu; John C van Swieten; Wolfgang H Oertel; Günter U Höglinger
Journal:  Mov Disord       Date:  2013-02-21       Impact factor: 10.338

3.  Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia.

Authors:  K A Josephs; B F Boeve; J R Duffy; G E Smith; D S Knopman; J E Parisi; R C Petersen; D W Dickson
Journal:  Neurocase       Date:  2005-08       Impact factor: 0.881

4.  Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias.

Authors:  O L Lopez; I Litvan; K E Catt; R Stowe; W Klunk; D I Kaufer; J T Becker; S T DeKosky
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

5.  Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy.

Authors:  P Soliveri; D Monza; D Paridi; F Carella; S Genitrini; D Testa; F Girotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

6.  Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia.

Authors:  Jennifer M Harris; Claire Gall; Jennifer C Thompson; Anna M T Richardson; David Neary; Daniel du Plessis; Piyali Pal; David M A Mann; Julie S Snowden; Matthew Jones
Journal:  Neurology       Date:  2013-04-17       Impact factor: 9.910

7.  Clinical features and survival of 3R and 4R tauopathies presenting as behavioral variant frontotemporal dementia.

Authors:  William T Hu; Joseph E Parisi; David S Knopman; Bradley F Boeve; Dennis W Dickson; J Eric Ahlskog; Ronald C Petersen; Keith A Josephs
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Oct-Dec       Impact factor: 2.703

Review 8.  Neuropathological background of phenotypical variability in frontotemporal dementia.

Authors:  Keith A Josephs; John R Hodges; Julie S Snowden; Ian R Mackenzie; Manuela Neumann; David M Mann; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2011-05-26       Impact factor: 17.088

9.  Emotion recognition in progressive supranuclear palsy.

Authors:  B C P Ghosh; J B Rowe; A J Calder; J R Hodges; T H Bak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-10       Impact factor: 10.154

10.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

View more
  20 in total

1.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Authors:  Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

Review 2.  Imaging pathological tau in atypical parkinsonian disorders.

Authors:  Sarah Coakeley; Antonio P Strafella
Journal:  Curr Opin Neurol       Date:  2015-08       Impact factor: 5.710

Review 3.  Gut Microbiota Disorder, Gut Epithelial and Blood-Brain Barrier Dysfunctions in Etiopathogenesis of Dementia: Molecular Mechanisms and Signaling Pathways.

Authors:  Menizibeya O Welcome
Journal:  Neuromolecular Med       Date:  2019-05-21       Impact factor: 3.843

4.  Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes.

Authors:  Andrea Horta-Barba; Javier Pagonabarraga; Saül Martínez-Horta; Laura Busteed; Berta Pascual-Sedano; Ignacio Illán-Gala; Juan Marin-Lahoz; Ignacio Aracil-Bolaños; Jesús Pérez-Pérez; Frederic Sampedro; Helena Bejr-Kasem; Jaime Kulisevsky
Journal:  J Neurol       Date:  2021-03-11       Impact factor: 4.849

Review 5.  Therapy and clinical trials in frontotemporal dementia: past, present, and future.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  J Neurochem       Date:  2016-06-15       Impact factor: 5.372

Review 6.  Neuroimaging in Dementia.

Authors:  Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind
Journal:  Semin Neurol       Date:  2017-12-05       Impact factor: 3.420

Review 7.  Frontotemporal Dementias.

Authors:  Elizabeth C Finger
Journal:  Continuum (Minneap Minn)       Date:  2016-04

Review 8.  Language impairment in progressive supranuclear palsy and corticobasal syndrome.

Authors:  Katie A Peterson; Karalyn Patterson; James B Rowe
Journal:  J Neurol       Date:  2019-07-18       Impact factor: 4.849

9.  DAPHNE: A New Tool for the Assessment of the Behavioral Variant of Frontotemporal Dementia.

Authors:  Claire Boutoleau-Bretonnière; Christelle Evrard; Jean Benoît Hardouin; Laëtitia Rocher; Tiphaine Charriau; Frédérique Etcharry-Bouyx; Sophie Auriacombe; Aurélie Richard-Mornas; Florence Lebert; Florence Pasquier; Anne Sauvaget; Samuel Bulteau; Martine Vercelletto; Pascal Derkinderen; Cédric Bretonnière; Catherine Thomas-Antérion
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2015-12-18

10.  Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes.

Authors:  Ian T S Coyle-Gilchrist; Katrina M Dick; Karalyn Patterson; Patricia Vázquez Rodríquez; Eileen Wehmann; Alicia Wilcox; Claire J Lansdall; Kate E Dawson; Julie Wiggins; Simon Mead; Carol Brayne; James B Rowe
Journal:  Neurology       Date:  2016-04-01       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.